Spotlighting Lessons Learned in Tumour Model Selection to Advance ADC Development
- Highlighting the pros and cons of CDX and PDX models
- Discussing strategies to empower tumour model selection to better study underserved patient populations
- Leveraging findings from the models to tackle ADC payload toxicity and dosing strategies for mice versus humans